Show simple item record

Characterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes

dc.contributor.authorVera, Gema
dc.contributor.authorLópez-Miranda, Visitación
dc.contributor.authorHerradón, Esperanza
dc.contributor.authorMartín, María Isabel
dc.contributor.authorAbalo, Raquel
dc.date.accessioned2014-05-28T14:21:45Z
dc.date.available2014-05-28T14:21:45Z
dc.date.issued2012
dc.identifier.citationCharacterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabetes Vera G., Lopez-Miranda V., Herradon E., Martin M.I., Abalo R. (2012) Pharmacology Biochemistry and Behavior, 102 (2) , pp. 335-343.
dc.identifier.issn0091-3057
dc.identifier.urihttp://hdl.handle.net/10115/12385
dc.description.abstractDiabetic neuropathy is a frequent complication of diabetes mellituswith a tremendous impact on patients' quality of life, and it remains poorly treated. Cannabinoids relieve the signs of diabetic neuropathy in different experimental models, including streptozotocin- (STZ-) induced type 1 diabetic rodents, and they may also relieve neuropathic signs in type 2 diabetic animals. This study compares the effect of the non-selective cannabinoid agonist WIN 55,212-2 (WIN) in Zucker Diabetic Fatty (ZDF) rats (type 2 diabetes) and in STZ-injected Wistar rats (type 1 diabetes). WIN (or its vehicle) was either systemically administered at a non-psychoactive dose or locally injected. Selective CB1 and CB2 cannabinoid antagonists were used to characterize WIN antineuropathic effects. Both type 1 and type 2 diabetic rats showed mechanical allodynia but not thermal hyperalgesia. WIN alleviated mechanical allodynia in both models of diabetes. In STZ-treated rats, both cannabinoid receptors were involved, whereas in ZDF rats, WIN effects seemed to mainly involve the activation of CB1 receptors. Higher doses of WIN were needed to significantly relieve mechanical allodynia upon intraplantar administration in ZDF vs. STZ-injected rats. Cannabinoids, acting on systemic and/or peripheral receptors, may serve as a new therapeutic alternative for symptom management in painful neuropathy associated with both type 1 and type 2 diabetes. Additionally, our results highlight the need for appropriate selection of diabetic experimental models because the results from studies in STZ-induced diabetic rodents might not be applicable in all diabetic situations.es
dc.language.isoenges
dc.publisherElsevieres
dc.relationS2010/BMD-2308
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectFarmaciaes
dc.subjectCannabinoides
dc.subjectNeuropathic paines
dc.subjectType 2 diabeteses
dc.subjectZucker Diabetic Fatty rates
dc.subjectType 1 diabeteses
dc.subjectStreptozotocines
dc.titleCharacterization of cannabinoid-induced relief of neuropathic pain in rat models of type 1 and type 2 diabeteses
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doi10.1016/j.pbb.2012.05.008es
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subject.unesco3207.11 Neuropatologíaes
dc.description.departamentoFarmacología, Nutrición y Bromatología


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 EspañaExcept where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España